Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) shot up 6.7% during mid-day trading on Friday . The company traded as high as $13.17 and last traded at $13.19. 129,790 shares changed hands during trading, a decline of 64% from the average session volume of 362,154 shares. The stock had previously closed at $12.36.
Analyst Ratings Changes
Several brokerages have commented on BCAX. RODMAN&RENSHAW upgraded Bicara Therapeutics to a "strong-buy" rating in a research note on Tuesday, November 5th. HC Wainwright boosted their target price on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a "buy" rating in a research note on Monday, January 27th. Rodman & Renshaw started coverage on shares of Bicara Therapeutics in a research report on Tuesday, November 5th. They issued a "buy" rating and a $48.00 price objective on the stock. Finally, Wedbush reiterated an "outperform" rating and issued a $31.00 price objective on shares of Bicara Therapeutics in a report on Wednesday, February 12th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Bicara Therapeutics has a consensus rating of "Buy" and a consensus target price of $41.20.
Check Out Our Latest Stock Report on BCAX
Bicara Therapeutics Trading Up 7.6 %
The firm has a 50 day moving average price of $13.82.
Institutional Investors Weigh In On Bicara Therapeutics
Hedge funds have recently bought and sold shares of the company. RA Capital Management L.P. acquired a new stake in Bicara Therapeutics in the 3rd quarter worth about $177,169,000. Red Tree Management LLC acquired a new stake in shares of Bicara Therapeutics during the fourth quarter valued at about $55,230,000. FMR LLC acquired a new position in Bicara Therapeutics in the 3rd quarter valued at approximately $57,913,000. Adage Capital Partners GP L.L.C. increased its holdings in Bicara Therapeutics by 171.9% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,175,265 shares of the company's stock valued at $37,893,000 after purchasing an additional 1,375,265 shares during the period. Finally, Braidwell LP increased its stake in shares of Bicara Therapeutics by 20.7% in the fourth quarter. Braidwell LP now owns 2,000,659 shares of the company's stock valued at $34,851,000 after buying an additional 343,059 shares during the period.
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Further Reading
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
